Opinion Pieces Discuss Issues Related To COVID-19 Vaccine Development, Distribution, Public Confidence, Access
The Conversation: Buying and distributing a COVID-19 vaccine will involve hard ethical and practical choices
Barbara Allen, senior lecturer in public management, and Michael Macaulay, professor of public administration, both at Te Herenga Waka — Victoria University of Wellington (11/17).
The Conversation: Virus evolution could undermine a COVID-19 vaccine — but this can be stopped
Andrew Read, Evan Pugh University professor of biology and entomology, Eberly professor of biotechnology, and director at the Huck Institutes of the Life Sciences at Penn State; and David Kennedy, assistant professor of biology at Penn State (11/17).
Foreign Policy: The World’s Wild and Crazy Vaccine Ride Is Just Starting
Laurie Garrett, former senior fellow for global health at the Council on Foreign Relations (11/17).
The Hill: Rebuilding public trust will instill COVID-19 vaccine confidence
Lyndon Haviland, distinguished scholar at the CUNY School of Public Health and Health Policy (11/17).
The Hill: Put the science into COVID communications
R. Craig Lefebvre, lead change designer at the Center for Communication Science at RTI International and author, and Glen Nowak, professor and director of the Grady College Center for Health & Risk Communication at the University of Georgia (11/17).
The Lancet Infectious Diseases: Vaccine innovation spurred by the long wait for an Ebola virus vaccine
Hugues Fausther-Bovendo, research associate, and Gary Kobinger, researcher, both at Centre de Recherche en Infectiologie de l’Université Laval (11/17).
Thomson Reuters Foundation: Opinion: Only a generic, not-for-profit COVID-19 vaccine can protect the world’s poorest
Shaz Memon, founder of Wells on Wheels (11/17).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.